Equities

European Healthcare Acquisition & Growth Company BV

European Healthcare Acquisition & Growth Company BV

Actions
  • Price (EUR)--
  • Today's Change--
  • Shares traded0.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

European Healthcare Acquisition & Growth Company BV is a Germany-based emerging-growth blank check company, also referred to as a special purpose acquisition company (SPAC). The Firm’s business purpose is to effect a merger, share exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The Company focuses its search for a potential target business in Europe, in such as Biotechnology and Specialty Pharma, Pharma Services, Medical Technology and Medical Devices, Diagnostic and Lab Services, Bioinformatics, as well as Life Science Tools.

  • Revenue in EUR (TTM)0.00
  • Net income in EUR3.74m
  • Incorporated2021
  • Employees--
  • Location
    European Healthcare Acquisition & Growth Company BVTheresienhoehe 28, c/o ALR Treuhand GmbHMUNICH 80338GermanyDEU
  • Websitehttps://www.ehc-company.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.